ReShape Lifesciences Inc. (RSLS) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a revenue decline due to competitive pressures, supply chain challenges, and regulatory risks, despite cost reductions. The merger and asset sales could enhance future growth, but immediate concerns overshadow these prospects. The Q&A lacks clarity, further adding uncertainty. Overall, the negative financial performance and risks outweigh the positive elements, leading to a likely negative stock price movement.
Key Financial Performance
Revenue (Q2 2024) $2 million, a decrease of $300,000 (13%) compared to Q2 2023 due to a decrease in sales volume primarily attributed to GLP-1 pharmaceuticals.
Revenue (6 months 2024) $3.9 million, a decrease of $600,000 (13%) compared to the same period in 2023 due to a decrease in sales volume primarily attributed to GLP-1 pharmaceuticals.
Gross Profit (Q2 2024) $1.1 million, slightly below $1.2 million for Q2 2023; gross profit margin increased to 58% from 53% due to reduction in overhead related costs, primarily payroll.
Gross Profit (6 months 2024) $2.3 million, down from $2.4 million in 2023; gross profit margin increased to 59% from 53% due to reduction in overhead related costs, primarily payroll.
Sales and Marketing Expenses (Q2 2024) $700,000, a decrease of $1.5 million (68%) compared to $2.2 million in Q2 2023, primarily due to a decrease in advertising and marketing spending.
Sales and Marketing Expenses (6 months 2024) $1.7 million, a decrease of $2.7 million (61%) compared to $4.4 million in 2023, primarily due to a decrease in advertising and marketing spending.
General and Administrative Expenses (Q2 2024) Approximately $2.1 million, a decrease of $300,000 (13%) compared to $2.4 million in Q2 2023, due to a reduction in payroll-related expenditures and a decline in staffing levels.
General and Administrative Expenses (6 months 2024) Approximately $4 million, a decrease of $2.7 million (40%) compared to $6.7 million in 2023, due to a reduction in payroll-related expenditures and a decline in staffing levels.
Research and Development Expenses (Q2 2024) $400,000, a decrease of $200,000 (33%) compared to $600,000 in Q2 2023, due to a reduction in consulting and clinical trials.
Research and Development Expenses (6 months 2024) $900,000, a decrease of $200,000 (18%) compared to approximately $1 million in 2023, due to a reduction in consulting and clinical trials.
Non-GAAP Adjusted EBITDA Loss (Q2 2024) $1.9 million, improved from a loss of $3.7 million in Q2 2023, primarily due to continued efforts to reduce overall costs.
Non-GAAP Adjusted EBITDA Loss (6 months 2024) $4.1 million, improved from a loss of $9.1 million in the same period last year, primarily due to continued efforts to reduce overall costs.
Net Working Capital (End of Q2 2024) Approximately $2.9 million, primarily due to cash and cash equivalents, including restricted cash totaling $1.2 million; the company remains debt-free.
Operating Highlights
LAP-Band 2.0 Flex Launch: The commercial launch of the redesigned LAP-Band 2.0 Flex is in the last phase of limited market release, with positive initial surgeon feedback.
Obesity Market Positioning: The company believes the market opportunity for the LAP-Band will increase over time, especially with the newly launched LAP-Band 2.0 Flex, as the stigma around obesity treatment has been normalized.
Cost Reduction Plan: ReShape has achieved approximately 45% lower operating expenses for the first half of 2024 compared to the previous year.
Sales and Marketing Expenses: Sales and marketing expenses decreased by $1.5 million to $700,000 for Q2 2024, attributed to a shift to targeted digital marketing.
General and Administrative Expenses: General and administrative expenses decreased by $300,000 to approximately $2.1 million for Q2 2024, due to reduced payroll and staffing.
R&D Expenses: Research and development expenses decreased by $200,000 to $400,000 for Q2 2024, primarily due to a pause in clinical trials.
Merger with Vyome Therapeutics: ReShape is pursuing a merger with Vyome Therapeutics, which will result in the formation of Vyome Holdings, Inc., focusing on immuno-inflammatory diseases.
Asset Sale to Biorad: An asset purchase agreement with Biorad for $5.16 million in cash will help fund the merger with Vyome.
Risk or Challenges
Competitive Pressures: The widespread adoption of GLP-1 receptor agonists has led to a decrease in sales volume for ReShape's products, impacting revenue negatively.
Regulatory Issues: The merger agreement with Vyome Therapeutics and the asset purchase agreement with Biorad may face regulatory scrutiny, which could delay or complicate the transactions.
Supply Chain Challenges: The company has paused clinical trial work to preserve cash, indicating potential supply chain or operational challenges in maintaining ongoing research and development.
Economic Factors: The overall economic environment and market conditions may affect the company's ability to execute its growth strategy and achieve anticipated revenue from the LAP-Band 2.0 FLEX.
Financial Stability: Despite achieving a 45% reduction in operating costs, the company reported a revenue decrease of $300,000 for Q2 2024 compared to the same period in 2023, indicating ongoing financial challenges.
Guidance & Outlook
Cost Reduction Plan: Executed a 2024 cost reduction plan leading to approximately 45% lower operating expenses for the first half of the year compared to last year.
LAP-Band 2.0 Flex Launch: Commercial launch of the redesigned LAP-Band 2.0 Flex is in the last phase of limited market release, with positive initial surgeon feedback.
Merger with Vyome Therapeutics: Announced merger agreement with Vyome Therapeutics, aiming to create a new entity called Vyome Holdings.
Asset Purchase Agreement with Biorad: Successfully negotiated an asset purchase agreement with Biorad for $5.16 million in cash.
Shareholder Value Maximization: Efforts to maximize stockholder value through strategic mergers and asset sales.
Future Revenue Expectations: Expect the market opportunity for LAP-Band to increase over time due to the limitations of GLP-1s.
Liquidity Projections: Anticipated cash flow projections suggest adequate liquidity to self-fund into the second half of 2025.
Private Placement Commitments: Commitments for a minimum $7.3 million private placement in the combined company, potentially upsized.
Financial Health Post-Merger: Vyome Holdings will have no debt and a clean capital structure, positioning for success in public markets.
Shareholder Return Plan
Asset Purchase Agreement: ReShape Lifesciences has entered into an asset purchase agreement with Biorad for $5.16 million in cash, which will help pay down costs associated with the Vyome transaction.
Cost Reduction Plan: The company has implemented a disciplined cost reduction plan, achieving approximately 45% lower operating expenses for the first half of 2024 compared to the previous year.
Merger Agreement: ReShape Lifesciences is pursuing a merger with Vyome Therapeutics, which is expected to enhance shareholder value and growth potential.
Private Placement Commitment: Vyome's current stockholders have committed to a minimum $7.3 million private placement in the combined company, which may be upsized through additional investments.
Key Q&A
Earnings Word Cloud
RSLS Transcript
The earnings call highlights a mix of positive and negative factors. The merger and asset purchase agreements are strategic moves that could enhance shareholder value, but there are risks associated with integration and market adoption challenges. Financial performance shows modest revenue growth and improved margins, but overall sales have contracted. The Q&A session reveals uncertainties about product development and market competition from GLP-1s. Despite cost reductions, the lack of strong guidance and the uncertainty in market adoption balance the positives, suggesting a neutral sentiment with limited short-term stock price movement.
The earnings call highlights a revenue decline due to competitive pressures, supply chain challenges, and regulatory risks, despite cost reductions. The merger and asset sales could enhance future growth, but immediate concerns overshadow these prospects. The Q&A lacks clarity, further adding uncertainty. Overall, the negative financial performance and risks outweigh the positive elements, leading to a likely negative stock price movement.
The earnings call reveals mixed signals. While cost reductions and a new partnership with Bio-Rad are positive, the decrease in revenue and gross profit due to GLP-1 drug competition is concerning. The Q&A section shows optimism about overcoming GLP-1 challenges, but management's lack of clarity on long-term impact and timelines tempers enthusiasm. The stock price is likely to remain stable in the short term, with minor fluctuations.
RSLS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
